Skip to Content
Merck
  • Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.

Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.

Journal of clinical pharmacy and therapeutics (2010-11-09)
S-H Hsiao, H-H Chen, C-H Chou, W-L Lin, P-Y Liu Yeh, T-J Wu
ABSTRACT

Hypersensitivity syndrome associated with teicoplanin has rarely been reported. We report a case with a preceding episode of vancomyin-related neutropenia. A 47-year-old female with cervical spine infection was treated with vancomycin. Neutropenia occurred after 17 days of vancomycin therapy. Vancomycin was changed to teicoplanin, and the neutropenia resolved 4 days later. After 11 days of teicoplanin therapy, a new episode of hypersensitivity syndrome manifested as fever, bilateral neck lymphadenopathy, mild wheezing, hepatitis and increased CRP occurred. Neutropenia and thrombocytopenia developed 3 days later. The patient's symptoms settled over 1 week following withdrawal of teicoplanin. Naranjo's ADR algorithm categorized the neutropenia associated with vancomycin and the hypersensitivity syndrome associated with teicoplanin as 'probable'.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Teicoplanin
Teicoplanin, European Pharmacopoeia (EP) Reference Standard
Teicoplanin for identification, European Pharmacopoeia (EP) Reference Standard